Advancell raised an oversubscribed $315 million Series D round to accelerate its push to become a fully integrated global radiopharma developer. The funding supports late-stage clinical development alongside efforts to build isotope supply and manufacturing infrastructure. The oversubscription highlights investor demand for vertically integrated radiopharmaceutical models as companies compete to secure supply chains and execution capacity.